StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) company profile

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)

Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%

About Immunocore

Biological Products, (No Diagnostic Substances), SIC 2836

The company is a commercial-stage biotechnology firm that discovers and develops immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune diseases. Using its proprietary off-the-shelf ImmTAX platform, which combines engineered soluble T-cell receptor targeting systems with tailored immune-modulating effectors, it advances therapies across oncology, viral infections, and autoimmune indications. Its lead commercial product, KIMMTRAK, treats adult patients with unresectable or metastatic uveal melanoma. Its customer base includes cancer patients, health systems, and healthcare providers, supported by commercial third-party payors, commercial insurers, managed healthcare organizations, and government health programs.

The company's commercial operations span global markets, with KIMMTRAK approved in 39 countries and commercially launched in 30 countries, including the United States, Germany, and France. It conducts commercialization both through an in-house sales force and via regional distribution partnerships across Canada, Australia, New Zealand, Israel, Europe, Latin America, Turkey, the Middle East, North Africa, and the Commonwealth of Independent States. Drug manufacturing is outsourced to contract facilities in Denmark and Germany, with packaging completed in the Netherlands. The provided text does not state the company's headquarters.

Summary of the business section of Immunocore's latest annual report, written by StockData.

Company profile

Company

Legal name
Immunocore Holdings plc
Founded
2008
Headquarters
Oxfordshire, X0
Address
90 Park Drive, Milton Park, Abingdon OX14 4RY
Phone
01235 5430281
Employees
524, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
X0
Fiscal year ends
December 31
Auditor
Deloitte LLP, Cambridge, United Kingdom

Stock & identifiers

Ticker
IMCR
Exchange
Nasdaq
IPO date
Feb 8, 2021
Shares outstanding
51M, Jul 31, 2026
Public float
$1.50B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1671927
CUSIP
45258D105
ISIN
US45258D1054
FIGI
BBG00YYCXFB9
Share class FIGI
BBG00YYCXG54
LEI
213800IUE3DFS84BVN18
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Bahija JallalCHIEF EXECUTIVE OFFICER, Director12,343
Travis Alan CoyChief Financial Officer–
Leger Tina Amber StCHIEF HR OFFICER1,119
David M. BermanHEAD OF R&D5,859
John GollSVP, FINANCE & CAO653
Siddharth KaulDirector–
Kristine PetersonDirector–
William PaoDirector–
Roy Steven HerbstDirector–
Peter John RatcliffeDirector333
John Irving BellDirector13,452
Julian BakerDirector–
Bros. Advisors Lp BakerDirector–
Bros. Advisors (GP) LLC BakerDirector1,405,421
Brothers Life Sciences LP BakerDirector–
667, L.P.Director2,051,711
Felix BakerDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.89M$12.16M$3.55M$80$112
FY2024$12.85M-$21.44M$3.35M$68$84
FY2023$11.68M$21.97M$2.93M$158$84
FY2022$8.01M$51.27M$0$132$81
FY2021$34.78M$71.31M$0$79$90

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Bahija Jallal
Chief Executive Officer
$765.00K–$2.82M$6.58M$688.50K$31.79K$10.89M-15%
Travis Coy
Chief Financial Officer
$500.00K$100.00K–$4.30M$250.00K$21.22K$5.17M–
Tina St. Leger
Chief Human Resources Officer
$374.95K–$250.89K$376.36K$179.97K$23.15K$1.20M+8%
David Berman
Former Executive Vice President, Head of Research & Development
$540.00K–$1.40M$2.10M$216.00K$23.01K$4.28M-22%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 8, 2021
Offer price
$26.00
Securities offered
9,935,896
Gross proceeds
$258.33M
Exchange
Nasdaq
First trading day
Feb 5, 2021
First-day close
$43.20+66.2%
Lock-up ends (est.)
Aug 4, 2021

“The initial public offering price per ADS is $26.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025 , we had 524 full-time employees who work primarily in the United Kingdom and the United States.”

Corporate history

Events identified from SEC filings

DateEventDetails
Feb 8, 2021IPOInitial public offering priced (424B4 prospectus)
Feb 2, 2021ListingRegistration of securities on an exchange (Form 8-A)
Feb 1, 2021Name changeName changed from Immunocore Ltd to Immunocore Holdings plc

See a number that looks wrong?